LUCIUS 卢修斯 贝舒地尔 Belumosudil慢性移植物 抗宿主病
LUCIUS 卢修斯 贝舒地尔 Belumosudil慢性移植物 抗宿主病
贝舒地尔
美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品
Belumosudil
老挝国家食药监局批准上市
老挝国家药检所检测认证
Rx Only
慢性移植物
Each film-coated tablet contains
Belumosudil mesvlate 242.5mg equrvalent
to Belumosudil.
Indication:
LuciBelu
抗宿主病
LuciBelu is a kiase inhibitor indicated for
the treatment of adult and pediatric patients
12 years and older with chronie graft-versus
host disease (chronic GVHD) after failura of
Belumosudil Tablets
at least two prior lines of systemic therapy
Dasasaand
Dosage and Use:py.
Recommended Dosage: 200 mg taken orallv
200mg
once daily with food.
FDA批准
Storage: in a dry place and store at 20℃ to
25C.
Warning:
Keep medicine out of reach of Children.
Do not administer LuciBe lu during
Pregnancy and Lactation.
PLEASESEE PACKAGE INSERT
Manufactured and Marketed by;
LUCIUS
权威认证
Vientiane Capital, Laos
age, Aaytnany districi,
30
Tablets
Warning: To be sold by retail on prescripti
eastered physicians only, and as direet
LUCIUS
PHARMACEUTICALS
口碑质量
适应症:
适用于12岁及以上的成人和儿童慢性移植物抗宿
主病(慢性GVHD)患者在至少两种既往全身治疗失
败后的治疗。
推荐剂量:
1 、 口 服 给 药 , 每 次 200mg, 每 日 一
2、整片吞下,随食物服用。
无法加载取货服务可用情况
99999 件存货
查看完整详细信息